Treatment Status for Generalized Pustular Psoriasis in Japanese Patients: A Retrospective Chart Review
In Japanese clinical practice, the evolution of treatment practices for GPP has seen an increased use of biologic therapies over time. Biologic use was common after flares; however, some flares occurred during biologic therapy, indicating a need for improved treatment options to maintain stable disease and prevent flares.
Authors
- Yukari Okubo (ORCID: https://orcid.org/0000-0002-9526-1259)
- Shinichi Imafuku
- Yayoi Tada (ORCID: https://orcid.org/0000-0003-3743-135X)
- Kazumitsu Sugiura (ORCID: https://orcid.org/0000-0002-5207-4592)
- Ryuhei Okuyama (ORCID: https://orcid.org/0000-0003-4360-6865)
- Keiichi Yamanaka (ORCID: https://orcid.org/0000-0003-3055-5202)
- Morihisa Saitoh
- Masahito Yasuda (ORCID: https://orcid.org/0000-0002-2907-640X)
- Yukie Yamaguchi (ORCID: https://orcid.org/0000-0002-0297-6627)
- Akimichi Morita (ORCID: https://orcid.org/0000-0001-8372-3754)
- Wataru Sakamoto (ORCID: https://orcid.org/0000-0003-4198-2242)
Institutions
- Shinshu University (JP)
- Tokyo Medical University (JP)
- Gunma University (JP)
- Mie University (JP)
- Fukuoka University (JP)
- Nagoya City University (JP)
- Boehringer Ingelheim (Japan) (JP)
- Fujita Health University Hospital (JP)
- Shinshu University Hospital (JP)
- Mizuho (Japan) (JP)
- Teikyo University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1007/s13555-025-01429-8
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Amgen
- Torii Pharmaceutical
- Boehringer Ingelheim Japan
- Eisai